Category: pharmacological
Aliases: Trintellix, Brintellix, Lu AA21004
Multimodal agent: SERT inhibition plus direct receptor-level modulation (5-HT3 + 5-HT7 + 5-HT1D antagonism, 5-HT1A full agonism, 5-HT1B partial agonism). The additional receptor actions are proposed to explain the cognitive-performance signal (processing speed, executive function) seen in some MDD trials and the lower GI side-effect burden vs classical SSRIs. Not an abrupt-withdrawal agent — long t½ smooths discontinuation.
PO: 57h